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Poster Session I S283Multiple viruses have been associated with HC, such as BK polyoma
virus (BKV), CMV, and Adenovirus.
Methods:Medical records of 30 pediatric pts who had undergone
allogeneic or autologous HCT at our center between March of
2007 and April of 2010 have been reviewed. Urine of all patients
was sent for quantitative BKV by PCR. BKV positive was consid-
ered as a load of $ 10E6 copies/ml. CMV was monitored quan-
titatively by PCR. Categorical tables were analyzed using
Pearson’s chi-square test and the Cochran-Mantel-Haenszel test.
Tabular and graphical descriptive survival analyses were per-
formed using cumulative incidence methods accounting for com-
peting risks.
Results:Median age at transplant was 12.3 yrs. Nineteen pts had al-
ternative donor HCT: 13 from a matched unrelated donor, 4 from
double cord blood units (CBU) and 2 from a single CBU. Ten
HCT were from matched related donors (MRD), including 1 with
MRD CBU. One pt had an autologous transplant. All pts had re-
ceived a full myeloablative conditioning therapy. Acute GVHD oc-
curred in 28 pts (96.5%); all were treated with methylprednisolone at
a median dose of 60mg daily. Out of 30 patients 10 (33.3%) patients
had HC at a median of 37 days post HCT (range 24 to 73 days). Five
(50%) had grade II HC, two pts (20%) hadmoderate grade III, and 3
(30%) had severe, grade IVHC.HCoccurred in 2 of 12 (17%) BKV-
pts compared with 8 of 18 (44%) BKV+ pts. (p 5 0.11). One of 10
CMV-, BKV- pts (10%) pts had HC; compared to 5 of 15 (33%)
of CMV+, BKV+ pts. (p 5 0.18). The occurrence of severe HC
was correlated with advanced disease state but not with higher ste-
roid doses.
Conclusion: BKV may play a role in HCT. A prospective study is
needed to better identify the role of BKV and CMV in the develop-
ment of HC.357
MEETING THE CHALLENGE: DEVELOPING A MODEL TO CARE FOR AN
ADOLESCENT PATIENT WITH LEUKEMIA AND SEVERE AUTISM
Bain,M.E.,Martin, P.L., Kojis, S., Trout, S.B., Kurtzberg, J. DukeUni-
verstiy Medical Center, Durham, NC; Duke University Medical Center,
Durham, NC; Duke University Medical Center, Durham, NC; Duke
University Medical Center, Durham, NC; Duke University Medical Cen-
ter, Durham, NC
As a Certified Child Life Specialist (CCLS) for the Duke Pediatric
Blood and Marrow Transplant program, one has to be prepared to
provide specialized services to all children. A CCLS has been trained
to incorporate age, diagnosis, developmental level and special needs
in the assessment of each patient. When a teenage girl with second-
ary leukemia and severe autismwas referred for a bonemarrow trans-
plant, all skills were put to the test. As a team, we worked proactively
to ensure a smooth and safe transition from her home hospital to our
transplant facility.
Our initial challenge was to anticipate the needs of this patient be-
fore we had a chance to meet her. A picture of the CCLS was taken
(labeled ‘‘a safe friend’’) and sent to the patient to begin building
a rapport. The CCLS, social worker and nurse coordinator corre-
sponded regularly with the patient’s caregiver before their arrival
to Durham. This dialogue provided our team with information
that helped form her detailed plan of care, and served as a base to
build a trusting relationship.
After learning about the patient’s communication style, photo-
graphs were taken of doctors, nurses, buildings, exam rooms, patient
room, hallway and waiting area, elevators, procedures, medical in-
struments - even mouth care brushes. The pictures were printed
and labeled with detailed descriptions using the five senses, then
mailed to the patient and family. Our goal was to prepare the patient
for a new care team and medical environment.
Our second challenge was to ensure a safe, trusting, and comfort-
able inpatient stay. Because disruptions to routine would often lead
to negative behavior, we provided a structured schedule, consistent
caregivers, and a plan designed to help the patient cope with unex-
pected events. The CCLSworked closely with the staff, psychosocial
team, and quality of life team educating them on the necessity to give
extra preparation time before transitions and/or procedures to allow
for successful cooperation from the patient. In addition, the patientresponded well to incentives (particularly food) to encourage coop-
eration for necessary daily activities.
This experience has provided our transplant team with a deeper
understanding of how to best serve these patients. The knowledge
gained helped us create a model to implement for future transplant
patients we encounter who fall within the autism spectrum.358
MULTIDISCIPLINARY CARE ON AN IN-PATIENT PEDIATRIC BLOOD AND
MARROW TRANSPLANT UNIT THAT DOES NOT INCLUDE RESIDENT PHY-
SICIANS
Kinsella, T.A., Jacobs, J.A., McLean, S.L., Turner, K., Tarin, R.,
Paff, Z.N., Wallace, G., Longhorn, E., Pesok, A., Eckstein, O.,
Baker, A.L., Berger, S., Bessler, L., Davies, S. Cincinnati Children’s
Hospital, Cincinnati, OH
The care of complex pediatric blood and marrow transplant
(BMT) patients requires numerous skilled and complimentary inter-
disciplinary caregivers. Changes in resident hours have altered the
balance of care givers on our team, which has not included residents
for the last five years. Primary bedside care is given by a team of col-
laborative advanced practive nurses (APN), hospitalists and fellows
seven days a week. Additional team members include in-patient
care managers (coordinators), pharmacists, dieticians, chaplains
and social workers. This team covers all aspects of care including
physical, educational, spiritual, cultural and psychosocial needs.
An attending physician oversees the daily intricate planning that is
carried out by the multidisciplinary team, and daily rounds are
conducted at the bedside with parents participating. Each child has
a primary care provider, either an APN, hospitalist or fellow. Presen-
tation of the child on rounds, order writing, lab interpretation, phys-
ical assessments and initiation of the care of the patient are
consistently managed by the primary care provider. Overnight care
is provided by a hospitalist who sleeps in house and works eight con-
secutive nights, providing continuity of care.
This structure, with limited contribution from rotating physicians
(only the fellows are on a ‘‘rotation’’), provides consistent care pro-
viders who are familiar with a patient’s long hospital course and
unit routines. This also provides a familiar face to families and pa-
tients who can often be readmitted.
The nurse care manager facilitates coordination of services such as
discharge planning, home care teaching, ordering home therapies
and supplies, scheduling and coordinating appointments of other
disciplines. The nurse care managers are also the primary educators
of BMT information to our families. The structure of our unit allows
for consistency, continuity of care and can be described as a solid
workforce and a comfort to those families undergoing BMT.359
VORICONAZOLE AS PRIMARY ANTIFUNGAL PROPHYLAXIS IN RECIPI-
ENTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FROM ALTERNATIVE DONORS
Cozzi, J., Basso, A., Lein, J., Saslavsky, J., Saslavsky, M., Pilli, V.
CETRAMOR BMT-Unit, Rosario, Santa Fe, Argentina
Background: Invasive Aspergillosis (IA) has been the leading cause
of death from fungal infections in patients undergoing allogeneic
Haematopoietic Stem Cell Transplantation (HSCT), particularly
from donors other than HLA-identical siblings.Given the high mor-
tality rate associated with IA and our inability to reliably diagnose ac-
tive cases, prophylactic therapy with Voriconazole (VOR) a triazole
with broad-spectrum antifungal activity against several molds, in-
cluding Aspergillus, was instituted as Primary Antifungal Prophy-
laxis (PAF-Px) in this high-risk group of patients.
Methods: from 02/09 to 02/10 nine patients(p) who underwent al-
ternative donor allogeneic HSCT and received VOR as PAF-Px
were studied.The patients received VOR 400 mg PO BID x 1 day,
then 200 mg PO BID.VOR was started the day of HSCT and
planned for 100 days.After day +100 VOR was continued in patients
requering corticosteroids for therapy of graft-versus-host-disease
(GVHD). Age,median(range)30(17-54)years. Male sex: 8 p
